Eli Lilly is set to report its first-quarter earnings, with Wall Street anticipating strong performance driven by new medicines. The company recently raised its full-year guidance following positive financial results for Q1 2026.
Additionally, optimism surrounding Lilly's new obesity pill has led to an upward revision of their sales forecast, indicating strong market momentum. Investors are closely watching these developments as they reflect Lilly's growth strategy and product pipeline.